Sign In
Buy ORGS
$0.590
+0.0950 (+19.19%)
At Close: Jun 03, 2026
Orgenesis says Ranpirnase advancing towards multiple indications after FDA consultation and presentation of positive results
08:46am, Tuesday, 06'th Jul 2021
Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) has announced multiple milestones in the development of Ranpirnase for multiple indications, including anogenital warts, adenoviral conjunctivitis and even corona
Wall Street climbs higher after inflation beats forecasts
12:17pm, Thursday, 10'th Jun 2021
12:15pm: S&P 500 goes for a record The Dow was up 108 points, 0.3%, to 34,555 at midday. The Nasdaq added 71 points, 0.5%, to 13,983, and the S&P improved 17 points, 0.4%, to 4,237, which would be a
Orgenesis says enrollment is underway for a Phase 2 rotator cuff repair study of its Tissue Genesis Icellator
08:56am, Thursday, 10'th Jun 2021
Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced that enrollment has commenced for a clinical trial using the company's Tissue Genesis Icellator in rotator cuff repair surgeries at the Hospital for Spe
Orgenesis: A Mispriced Visionary In Cell And Gene Therapy Manufacturing
10:31am, Monday, 17'th May 2021
Orgenesis: A Mispriced Visionary In Cell And Gene Therapy Manufacturing
Orgenesis Inc. (ORGS) CEO Vered Caplan on Q1 2021 Results - Earnings Call Transcript
11:09am, Monday, 10'th May 2021
Orgenesis Inc. (ORGS) CEO Vered Caplan on Q1 2021 Results - Earnings Call Transcript
ORGS Stock: Over 10% Increase Intraday Explanation
10:40am, Friday, 07'th May 2021
The stock price of Orgenesis Inc (NASDAQ: ORGS) increased by over 10% during intraday trading. This is why it happened.
Orgenesis reports four-fold increase in revenue in 1Q as it continues to grow its POCare strategy
09:11am, Friday, 07'th May 2021
Orgenesis Inc (NASDAQ:ORGS) (FRA:45O), the cell and gene therapies (CGTs) focused biotech, reported a four-fold increase in revenue in its first quarter to end-March, as the company continues its jour
Wall Street mixed at midday despite better than expected jobs data
12:22pm, Thursday, 06'th May 2021
12:20pm: Pharmaceutical stocks fall The Dow was up 162 points, 0.5%, to 34,393 at midday. The Nasdaq was ticked down 7 points to 13,576, and the S&P 500 picked up 12 points, 0.3%, to 4,180.
ORGS Stock: 14.06% Increase Pre-Market (From $4.48 To $5.11) Explanation
08:43am, Thursday, 06'th May 2021
The stock price of Orgenesis Inc (NASDAQ: ORGS) increased 14.06% pre-market (from $4.48 to $5.11). This is why it happened.
Orgenesis reaches milestone with US FDA approval of Tissue Genesis Icellator2 pilot trial
08:24am, Thursday, 06'th May 2021
Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) is poised to carry out the first-in-human trial of its Tissue Genesis Icellator2 to treat Acute Respiratory Distress Syndrome (ARDS) caused by the coronavirus (CO
Orgenesis to collaborate with Bambino Gesù Children's Hospital in Rome on new therapy centre
09:35am, Monday, 29'th Mar 2021
Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) has announced a tie-up with Rome's Bambino Gesù children's hospital in Rome, Italy to establish a point-of-care cell therapy centre there. Work will focus on
Orgenesis to collaboration with Bambino Gesù Children's Hospital in Rome on new therapy centre
09:27am, Monday, 29'th Mar 2021
Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) has announced a tie-up with Rome's Bambino Gesù children's hospital - the first such hospital in Italy - to establish a point-of-care cell therapy centre there.
GERMANTOWN, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and ge
Orgenesis Inc (NASDAQ:ORGS) announced Thursday that it is collaborating with MIDA Biotech BV to establish point-of-care centers at hospitals and other medical institutions across western Europe. Orge
Orgenesis collaboration with Madrid hospital to develop solid tumor treatment Celyvir enters second phase
09:41am, Thursday, 11'th Mar 2021
Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced Thursday that it has entered the second phase of its collaboration with Hospital Infantil Universitario Niño Jesús in Madrid, Spain, focused on the ho
